 Daniel Pastula
Concepts (214)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Zika Virus Infection | 9 | 2018 | 83 | 2.290 |
Why?
| | Encephalitis, California | 4 | 2019 | 11 | 1.860 |
Why?
| | Epilepsy | 6 | 2023 | 278 | 1.560 |
Why?
| | Guillain-Barre Syndrome | 5 | 2017 | 21 | 1.520 |
Why?
| | Encephalitis, Tick-Borne | 3 | 2023 | 8 | 1.420 |
Why?
| | Disease Outbreaks | 8 | 2023 | 309 | 1.400 |
Why?
| | Sexual and Gender Minorities | 2 | 2022 | 138 | 1.380 |
Why?
| | Flavivirus Infections | 2 | 2019 | 9 | 1.370 |
Why?
| | Amyotrophic Lateral Sclerosis | 6 | 2015 | 61 | 1.360 |
Why?
| | Bunyaviridae Infections | 3 | 2019 | 6 | 1.300 |
Why?
| | Central Nervous System Diseases | 2 | 2023 | 61 | 1.300 |
Why?
| | Monkeypox virus | 3 | 2023 | 12 | 1.260 |
Why?
| | Nervous System Diseases | 4 | 2023 | 252 | 1.140 |
Why?
| | Chikungunya Fever | 2 | 2017 | 61 | 1.030 |
Why?
| | Meningitis | 2 | 2023 | 74 | 1.020 |
Why?
| | Encephalitis | 3 | 2023 | 127 | 0.990 |
Why?
| | Medical Tourism | 1 | 2023 | 9 | 0.880 |
Why?
| | Arbovirus Infections | 2 | 2023 | 17 | 0.880 |
Why?
| | Smallpox Vaccine | 1 | 2023 | 22 | 0.870 |
Why?
| | Flavivirus | 2 | 2019 | 16 | 0.850 |
Why?
| | Optic Neuritis | 1 | 2023 | 37 | 0.840 |
Why?
| | Encephalomyelitis | 1 | 2022 | 9 | 0.840 |
Why?
| | Encephalitis Virus, California | 3 | 2019 | 6 | 0.810 |
Why?
| | Phlebovirus | 3 | 2020 | 4 | 0.810 |
Why?
| | Exanthema | 1 | 2022 | 76 | 0.790 |
Why?
| | Mycobacterium abscessus | 1 | 2023 | 98 | 0.780 |
Why?
| | Creatine | 2 | 2012 | 50 | 0.770 |
Why?
| | Neuroprotective Agents | 2 | 2012 | 105 | 0.730 |
Why?
| | Acyclovir | 1 | 2020 | 100 | 0.690 |
Why?
| | Encephalomyelitis, Eastern Equine | 1 | 2019 | 6 | 0.680 |
Why?
| | Neurology | 2 | 2019 | 84 | 0.680 |
Why?
| | Lymphohistiocytosis, Hemophagocytic | 2 | 2018 | 28 | 0.660 |
Why?
| | Mycobacterium Infections, Nontuberculous | 1 | 2023 | 336 | 0.620 |
Why?
| | Thrombocytopenia | 2 | 2017 | 178 | 0.620 |
Why?
| | Myelitis | 4 | 2021 | 88 | 0.570 |
Why?
| | Hepatitis E | 1 | 2017 | 2 | 0.570 |
Why?
| | Hepatitis E virus | 1 | 2017 | 2 | 0.570 |
Why?
| | Epidemiological Monitoring | 1 | 2017 | 48 | 0.560 |
Why?
| | Dengue | 1 | 2016 | 59 | 0.520 |
Why?
| | Communicable Diseases, Emerging | 1 | 2016 | 28 | 0.520 |
Why?
| | Humans | 49 | 2023 | 115038 | 0.490 |
Why?
| | Antiviral Agents | 1 | 2020 | 647 | 0.480 |
Why?
| | Ixodidae | 1 | 2014 | 5 | 0.470 |
Why?
| | Zika Virus | 5 | 2018 | 59 | 0.460 |
Why?
| | Critical Care | 1 | 2017 | 475 | 0.430 |
Why?
| | Enterovirus Infections | 3 | 2021 | 160 | 0.380 |
Why?
| | Homosexuality, Male | 2 | 2022 | 170 | 0.380 |
Why?
| | Meningoencephalitis | 2 | 2021 | 24 | 0.360 |
Why?
| | Male | 24 | 2023 | 55729 | 0.320 |
Why?
| | Infant | 9 | 2022 | 7945 | 0.320 |
Why?
| | United States | 10 | 2023 | 12224 | 0.300 |
Why?
| | Population Surveillance | 4 | 2018 | 392 | 0.300 |
Why?
| | Fatal Outcome | 4 | 2018 | 285 | 0.290 |
Why?
| | Muscle Hypotonia | 2 | 2018 | 31 | 0.290 |
Why?
| | Child, Preschool | 8 | 2022 | 9093 | 0.290 |
Why?
| | North America | 2 | 2019 | 259 | 0.290 |
Why?
| | Motor Neuron Disease | 3 | 2012 | 16 | 0.280 |
Why?
| | Culicidae | 2 | 2016 | 29 | 0.260 |
Why?
| | Animals | 11 | 2023 | 31867 | 0.250 |
Why?
| | Infant, Newborn | 4 | 2022 | 5040 | 0.250 |
Why?
| | Enterovirus D, Human | 2 | 2016 | 72 | 0.240 |
Why?
| | Child | 10 | 2022 | 18407 | 0.240 |
Why?
| | Rituximab | 2 | 2023 | 150 | 0.230 |
Why?
| | Glial Fibrillary Acidic Protein | 2 | 2023 | 79 | 0.230 |
Why?
| | Middle Aged | 11 | 2020 | 26826 | 0.220 |
Why?
| | Autoimmune Diseases of the Nervous System | 1 | 2023 | 21 | 0.220 |
Why?
| | Myelin-Oligodendrocyte Glycoprotein | 1 | 2023 | 44 | 0.220 |
Why?
| | Adolescent | 10 | 2023 | 17862 | 0.210 |
Why?
| | Encephalitis, Viral | 1 | 2023 | 39 | 0.210 |
Why?
| | District of Columbia | 1 | 2022 | 25 | 0.210 |
Why?
| | West Nile Fever | 1 | 2023 | 50 | 0.210 |
Why?
| | Registries | 1 | 2009 | 1763 | 0.200 |
Why?
| | Adult | 11 | 2023 | 30654 | 0.190 |
Why?
| | Enterovirus A, Human | 1 | 2021 | 12 | 0.190 |
Why?
| | Age of Onset | 2 | 2015 | 449 | 0.190 |
Why?
| | Acute Disease | 4 | 2018 | 915 | 0.190 |
Why?
| | Disease Progression | 4 | 2012 | 2389 | 0.180 |
Why?
| | Colorado | 3 | 2022 | 4089 | 0.180 |
Why?
| | Young Adult | 6 | 2023 | 10498 | 0.180 |
Why?
| | Vital Capacity | 2 | 2012 | 257 | 0.180 |
Why?
| | Incidence | 5 | 2018 | 2318 | 0.180 |
Why?
| | Central Nervous System Viral Diseases | 1 | 2021 | 63 | 0.180 |
Why?
| | Hashimoto Disease | 1 | 2020 | 9 | 0.180 |
Why?
| | Simplexvirus | 1 | 2020 | 80 | 0.170 |
Why?
| | Interferon-gamma | 1 | 2023 | 723 | 0.170 |
Why?
| | Neuromuscular Diseases | 1 | 2021 | 89 | 0.170 |
Why?
| | Administration, Intravenous | 1 | 2020 | 125 | 0.170 |
Why?
| | Bunyamwera virus | 1 | 2019 | 3 | 0.170 |
Why?
| | Aged | 9 | 2018 | 19119 | 0.170 |
Why?
| | Seizures | 1 | 2022 | 341 | 0.160 |
Why?
| | Immunologic Factors | 1 | 2021 | 221 | 0.160 |
Why?
| | Immunoglobulin G | 1 | 2023 | 776 | 0.160 |
Why?
| | Stem Cells | 1 | 2023 | 546 | 0.160 |
Why?
| | Central Nervous System Infections | 1 | 2019 | 36 | 0.160 |
Why?
| | Autopsy | 2 | 2015 | 85 | 0.160 |
Why?
| | Veterans | 1 | 2009 | 1238 | 0.160 |
Why?
| | Magnetic Resonance Imaging | 2 | 2023 | 3116 | 0.160 |
Why?
| | La Crosse virus | 1 | 2017 | 6 | 0.150 |
Why?
| | Skin | 1 | 2022 | 659 | 0.150 |
Why?
| | Motor Disorders | 1 | 2018 | 16 | 0.150 |
Why?
| | Randomized Controlled Trials as Topic | 3 | 2012 | 1214 | 0.150 |
Why?
| | Fever | 2 | 2017 | 280 | 0.150 |
Why?
| | Female | 15 | 2021 | 59610 | 0.140 |
Why?
| | Pandemics | 2 | 2023 | 1321 | 0.140 |
Why?
| | Micronesia | 1 | 2017 | 3 | 0.140 |
Why?
| | Encephalomyelitis, Equine | 1 | 2016 | 1 | 0.140 |
Why?
| | Encephalitis Virus, Eastern Equine | 1 | 2016 | 2 | 0.140 |
Why?
| | International Classification of Diseases | 1 | 2017 | 116 | 0.140 |
Why?
| | Fiji | 1 | 2016 | 3 | 0.140 |
Why?
| | Diagnostic Errors | 1 | 2017 | 151 | 0.140 |
Why?
| | Antibodies, Viral | 4 | 2023 | 522 | 0.140 |
Why?
| | Health Surveys | 1 | 2018 | 443 | 0.140 |
Why?
| | Aged, 80 and over | 3 | 2017 | 6357 | 0.130 |
Why?
| | Arthropod Vectors | 1 | 2016 | 7 | 0.130 |
Why?
| | Ticks | 1 | 2016 | 12 | 0.130 |
Why?
| | Encephalitis Viruses, Tick-Borne | 1 | 2016 | 7 | 0.130 |
Why?
| | Neurologic Examination | 1 | 2016 | 115 | 0.130 |
Why?
| | T-Lymphocytes | 1 | 2023 | 1747 | 0.130 |
Why?
| | Lyme Disease | 1 | 2015 | 32 | 0.130 |
Why?
| | Thogotovirus | 1 | 2015 | 1 | 0.130 |
Why?
| | Chikungunya virus | 1 | 2016 | 61 | 0.120 |
Why?
| | Health Services Needs and Demand | 1 | 2017 | 245 | 0.120 |
Why?
| | Pregnancy Complications, Infectious | 1 | 2018 | 287 | 0.120 |
Why?
| | Quality of Life | 2 | 2022 | 2359 | 0.110 |
Why?
| | Plant Oils | 1 | 2013 | 27 | 0.110 |
Why?
| | Curriculum | 1 | 2019 | 843 | 0.110 |
Why?
| | Cluster Analysis | 1 | 2014 | 458 | 0.110 |
Why?
| | Models, Statistical | 1 | 2017 | 602 | 0.110 |
Why?
| | Age Factors | 2 | 2018 | 2894 | 0.110 |
Why?
| | Linear Models | 1 | 2015 | 776 | 0.100 |
Why?
| | Puerto Rico | 3 | 2017 | 52 | 0.100 |
Why?
| | Case-Control Studies | 2 | 2016 | 3015 | 0.100 |
Why?
| | Biopsy | 1 | 2015 | 1046 | 0.100 |
Why?
| | Parkinson Disease | 1 | 2015 | 323 | 0.100 |
Why?
| | Emergency Service, Hospital | 1 | 2022 | 1811 | 0.100 |
Why?
| | Hospitalization | 2 | 2017 | 1754 | 0.100 |
Why?
| | Health Promotion | 1 | 2017 | 686 | 0.090 |
Why?
| | Multiple Sclerosis | 1 | 2015 | 380 | 0.090 |
Why?
| | Alzheimer Disease | 1 | 2015 | 436 | 0.090 |
Why?
| | Vietnam | 1 | 2009 | 21 | 0.090 |
Why?
| | Muscle Cramp | 1 | 2009 | 7 | 0.080 |
Why?
| | Piracetam | 1 | 2009 | 14 | 0.080 |
Why?
| | Influenza, Human | 1 | 2015 | 546 | 0.080 |
Why?
| | Dietary Supplements | 1 | 2013 | 458 | 0.080 |
Why?
| | Muscle Spasticity | 1 | 2009 | 53 | 0.080 |
Why?
| | Anticonvulsants | 1 | 2009 | 178 | 0.070 |
Why?
| | Kaplan-Meier Estimate | 1 | 2009 | 814 | 0.070 |
Why?
| | Proportional Hazards Models | 1 | 2009 | 1080 | 0.070 |
Why?
| | United States Department of Veterans Affairs | 1 | 2009 | 557 | 0.070 |
Why?
| | Brain | 1 | 2017 | 2379 | 0.060 |
Why?
| | Survival Rate | 1 | 2009 | 1646 | 0.060 |
Why?
| | Clinical Trials as Topic | 1 | 2008 | 937 | 0.060 |
Why?
| | Astrocytes | 1 | 2023 | 162 | 0.050 |
Why?
| | Eosinophils | 1 | 2023 | 281 | 0.050 |
Why?
| | Cross Reactions | 1 | 2020 | 117 | 0.050 |
Why?
| | Microspheres | 1 | 2020 | 123 | 0.040 |
Why?
| | Immunoassay | 1 | 2020 | 95 | 0.040 |
Why?
| | Antigens, Viral | 1 | 2020 | 176 | 0.040 |
Why?
| | Immunoglobulin M | 1 | 2020 | 251 | 0.040 |
Why?
| | Delphi Technique | 1 | 2019 | 163 | 0.040 |
Why?
| | B-Lymphocytes | 1 | 2023 | 772 | 0.040 |
Why?
| | Missouri | 1 | 2018 | 63 | 0.040 |
Why?
| | Antineoplastic Agents, Immunological | 1 | 2020 | 152 | 0.040 |
Why?
| | Epilepsia Partialis Continua | 1 | 2017 | 3 | 0.040 |
Why?
| | Epilepsy, Generalized | 1 | 2017 | 13 | 0.040 |
Why?
| | Paraplegia | 1 | 2017 | 52 | 0.040 |
Why?
| | Ohio | 1 | 2017 | 136 | 0.040 |
Why?
| | Epilepsies, Partial | 1 | 2017 | 29 | 0.040 |
Why?
| | Insurance, Major Medical | 1 | 2017 | 2 | 0.040 |
Why?
| | Microcephaly | 1 | 2018 | 52 | 0.040 |
Why?
| | Medical Records | 1 | 2017 | 155 | 0.040 |
Why?
| | Arkansas | 1 | 2016 | 13 | 0.040 |
Why?
| | Muscle Weakness | 1 | 2017 | 80 | 0.040 |
Why?
| | Serogroup | 1 | 2016 | 26 | 0.040 |
Why?
| | Serologic Tests | 1 | 2016 | 49 | 0.030 |
Why?
| | Headache | 1 | 2017 | 132 | 0.030 |
Why?
| | Monte Carlo Method | 1 | 2017 | 137 | 0.030 |
Why?
| | Long-Term Care | 1 | 2017 | 76 | 0.030 |
Why?
| | Immunocompromised Host | 1 | 2018 | 196 | 0.030 |
Why?
| | Self-Management | 1 | 2018 | 126 | 0.030 |
Why?
| | Autoantibodies | 1 | 2023 | 1354 | 0.030 |
Why?
| | Public Health Surveillance | 1 | 2016 | 61 | 0.030 |
Why?
| | Spasms, Infantile | 1 | 2017 | 104 | 0.030 |
Why?
| | Electroencephalography | 1 | 2017 | 362 | 0.030 |
Why?
| | Geographic Mapping | 1 | 2015 | 21 | 0.030 |
Why?
| | Kansas | 1 | 2015 | 29 | 0.030 |
Why?
| | Pregnancy | 2 | 2018 | 5519 | 0.030 |
Why?
| | Immunoglobulins, Intravenous | 1 | 2016 | 121 | 0.030 |
Why?
| | Forecasting | 1 | 2017 | 332 | 0.030 |
Why?
| | Vaccination | 1 | 2023 | 1205 | 0.030 |
Why?
| | Genome, Viral | 1 | 2015 | 119 | 0.030 |
Why?
| | Neurodegenerative Diseases | 1 | 2015 | 91 | 0.030 |
Why?
| | Public Health | 1 | 2018 | 435 | 0.030 |
Why?
| | Coconut Oil | 1 | 2013 | 2 | 0.030 |
Why?
| | Nutrition Therapy | 1 | 2013 | 31 | 0.030 |
Why?
| | Clinical Competence | 1 | 2019 | 899 | 0.030 |
Why?
| | Databases, Factual | 1 | 2017 | 1132 | 0.030 |
Why?
| | Prevalence | 1 | 2018 | 2255 | 0.030 |
Why?
| | RNA, Viral | 1 | 2015 | 567 | 0.020 |
Why?
| | Phylogeny | 1 | 2015 | 796 | 0.020 |
Why?
| | Treatment Outcome | 2 | 2016 | 9122 | 0.020 |
Why?
| | Placebos | 1 | 2009 | 198 | 0.020 |
Why?
| | Review Literature as Topic | 1 | 2008 | 61 | 0.020 |
Why?
| | Anti-Bacterial Agents | 1 | 2016 | 1477 | 0.020 |
Why?
| | Tomography, X-Ray Computed | 1 | 2016 | 2341 | 0.020 |
Why?
| | Surveys and Questionnaires | 1 | 2018 | 4631 | 0.020 |
Why?
| | Biomarkers | 1 | 2016 | 3419 | 0.020 |
Why?
| | Time Factors | 1 | 2016 | 6141 | 0.020 |
Why?
| | Data Collection | 1 | 2008 | 623 | 0.020 |
Why?
| | Risk Factors | 1 | 2018 | 8642 | 0.020 |
Why?
| | Pilot Projects | 1 | 2009 | 1375 | 0.020 |
Why?
| | Research Design | 1 | 2008 | 930 | 0.010 |
Why?
| | Biomedical Research | 1 | 2008 | 585 | 0.010 |
Why?
| | Retrospective Studies | 1 | 2016 | 12547 | 0.010 |
Why?
|
|
Pastula's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|